Comparative Pharmacology
Head-to-head clinical analysis: MILONTIN versus NEURONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MILONTIN versus NEURONTIN.
MILONTIN vs NEURONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.
Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.
300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in adults, longer in children (8–12 hours) and elderly (10–14 hours); clinical context: requires multiple daily dosing to maintain therapeutic levels.
Terminal elimination half-life is 5–7 hours in patients with normal renal function; in elderly or those with renal impairment, half-life may be prolonged up to 132 hours; requires dose adjustment for creatinine clearance <60 mL/min.
Primarily hepatic metabolism and renal excretion; approximately 60% of a dose is excreted in urine as conjugated metabolite (phensuximide glucuronide), with 15% as unchanged drug; 20% eliminated in feces.
Renal elimination as unchanged drug: >90%; 0.3% is excreted in feces; biliary elimination is negligible.
Category C
Category C
Antiepileptic
Antiepileptic